Educational catalog
Peptides.
Educational information. Each entry shows its FDA regulatory status.
5-Amino-1MQ (NNMT Inhibitor) Selective NNMT inhibitor that preserves nicotinamide for NAD+ synthesis, activating SIRT1 and promoting fat oxidation in animal models of obesity. metabolic-weight-loss
Not FDA approved AICAR (AMPK Activator) Nucleotide analog that activates AMPK intracellularly, generating metabolic adaptations similar to prolonged aerobic exercise in animal models. metabolic-performance
Not FDA approved AOD-9604 Synthetic fragment of human growth hormone (amino acids 176–191). Retains the lipolytic effects of GH without its anabolic effects or impact on glucose/IGF-1. Studied specifically for fat loss. metabolic-weight-loss
Not FDA approved Argireline Synthetic hexapeptide studied for its ability to inhibit neurotransmitter release at the dermal-muscle junction, potentially reducing the appearance of expression lines when applied topically. cosmetic-topical
Not FDA approved BPC-157 Synthetic 15-amino-acid peptide derived from a gastric protein sequence, studied in tissue-repair models. healing-recovery
Not FDA approved Cagrilintide Long-acting acylated amylin analogue that acts on central amylin receptors. In combination with semaglutide 2.4 mg (CagriSema), produced ~20% weight loss at 68 weeks in Phase 3 trials. metabolic-weight-loss
Investigational CJC-1295 DAC A 30-amino-acid synthetic GHRH analog equipped with a Drug Affinity Complex that extends its half-life to 6-8 days through serum albumin binding, enabling weekly dosing and sustained GH and IGF-1 elevation. gh-secretagogue
Not FDA approved CJC-1295 No DAC Synthetic analog of GHRH (growth hormone-releasing hormone) with an extended half-life of ~30 minutes. Stimulates the pituitary to increase the amplitude of natural GH pulses. growth-hormone-performance
Not FDA approved CJC-1295 No DAC A 29-amino-acid synthetic GHRH analog with four amino acid substitutions that improve stability over native GHRH. Releases GH in a physiologically pulsatile pattern and is classically combined with Ipamorelin as the GHRH+GHRP stack. gh-secretagogue
Not FDA approved DSIP (Delta Sleep-Inducing Peptide) Endogenous nonapeptide that promotes deep, restorative delta sleep, modulates nocturnal growth hormone secretion, reduces cortisol, and acts as an adaptogen against oxidative stress. sleep-neurological
Not FDA approved Epithalon Synthetic tetrapeptide (Ala-Glu-Asp-Gly) analog of epithalamin, a protein extracted from the pineal gland. Activates telomerase in human cells in vitro and has demonstrated lifespan extension in animal models. longevity-mitochondrial-health
Not FDA approved GHK-Cu Copper tripeptide (Gly-His-Lys) that occurs naturally in human plasma. Stimulates collagen synthesis, activates anti-aging genes, and has documented wound-healing and anti-inflammatory properties. skin-cosmetic
Not FDA approved GHK-Cu (Topical) Topical formulation of the copper-binding tripeptide GHK-Cu, studied for stimulating collagen synthesis, antioxidant activity, and wound-healing signaling when applied to skin surface. cosmetic-topical
Not FDA approved GHRP-2 A synthetic hexapeptide ghrelin receptor agonist (GHS-R1a) that stimulates pulsatile GH release from the anterior pituitary. Has a cleaner profile than GHRP-6 with less appetite stimulation, and combines optimally with GHRH analogs for maximum synergy. gh-secretagogue
Not FDA approved GHRP-6 An enkephalin analog hexapeptide and GHS-R1a agonist with stronger ghrelinergic effects than GHRP-2. Produces potent GH stimulation with notable appetite increase, making it useful in caloric deficit contexts. Combines with CJC-1295 No DAC for maximum post-exercise GH release. gh-secretagogue
Not FDA approved Glutathione (GSH) Endogenous antioxidant tripeptide considered the body's primary intracellular antioxidant. Administered subcutaneously, it offers significantly higher bioavailability than oral routes (<2%). Investigated for its role in hepatic detoxification, immune modulation, and systemic oxidative stress reduction. antioxidant
Not FDA approved Gonadorelin (Native GnRH) Endogenous decapeptide (native GnRH) that stimulates pulsatile LH and FSH release from the pituitary; used in research as hormonal support and in reproductive medicine. hormonal-fertility
FDA approved HGH 191aa / Recombinant Somatropin Recombinant human somatropin with a 191 amino acid chain, identical to endogenous growth hormone. Activates GHR receptors to stimulate hepatic IGF-1 synthesis, promoting muscle anabolism, lipolysis, and tissue regeneration. growth-hormone
FDA approved Human Chorionic Gonadotropin (HCG) Glycoprotein gonadotropin that activates LH/hCG receptors in the gonads, stimulating endogenous testosterone production in Leydig cells and progesterone in the corpus luteum. Used in research for testicular maintenance during TRT, male fertility, and HPG axis restoration. hormonal-fertility
FDA approved IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) Recombinant variant of IGF-1 with extended half-life (20-30 h), studied in models of protein synthesis, muscle hyperplasia, and lipolysis. growth-factor
Not FDA approved Ipamorelin Selective growth hormone secretagogue (GH). Stimulates the pituitary to release GH in a pulsatile manner without elevating cortisol, prolactin, or ACTH. Considered one of the most selective GHRPs available. growth-hormone-performance
Not FDA approved Kisspeptin Neuropeptide (54aa; active fragment KP-10) that activates the GPR54 receptor on hypothalamic GnRH neurons, triggering the GnRH → LH/FSH → gonadal steroidogenesis cascade. Master regulator of the reproductive axis with research applications in functional hypothalamic amenorrhea, male fertility, and low-risk ovulatory triggering. hormonal-fertility
Investigational KPV Tripeptide (Lys-Pro-Val) derived from the C-terminal end of α-MSH. Potent intestinal anti-inflammatory in preclinical models. Acts directly on immune cells without the systemic effects of α-MSH or MTII. immune-inflammation
Not FDA approved L-Carnitine (Injectable) Amino acid derivative essential for transporting long-chain fatty acids into the mitochondria for oxidation. SC route offers ~100% bioavailability versus 5-18% oral, and avoids conversion to TMAO by intestinal microbiota. Investigated for body composition improvement, fatigue reduction, and cardiovascular support. metabolic-weight-loss
FDA approved Leuphasyl Opioid-receptor-modulating pentapeptide studied for reducing neuronal excitability at the dermal-muscular junction, used synergistically with Argireline in expression-line formulations. cosmetic-topical
Not FDA approved Matrixyl Lipopeptide studied for its ability to stimulate collagen and fibronectin synthesis in dermal fibroblasts, positioning it as a collagen-signaling active in anti-aging formulations. cosmetic-topical
Not FDA approved Mazdutide Long-acting dual GLP-1/glucagon agonist developed by Innovent Biologics. The glucagon component increases energy expenditure beyond the GLP-1 effect, with 11–14% weight loss in 48-week Phase 3 trials. metabolic-weight-loss
Investigational Melanotan II Cyclic analog of α-MSH with high affinity for melanocortin receptors MC1R–MC5R. Produces tanning, increases libido, and may reduce appetite. Potentially the most potent known sexual secretagogue. hormonal-sexual-health
Not FDA approved MOTS-c Mitochondrial peptide discovered in 2015 that acts as an exercise mimetic. Improves insulin sensitivity, activates AMPK, and in animal models improves longevity and metabolic resilience to aging. longevity-mitochondrial-health
Not FDA approved NAD+ Essential coenzyme present in all living cells, cofactor for more than 500 enzymes. Levels decline ~50% between ages 40 and 60. NAD+ replenishment activates sirtuins and PARP, with documented effects on energy, cognition, and DNA repair. longevity-mitochondrial-health
Not FDA approved Oxytocin Endogenous hormonal nonapeptide that activates OXTR receptors in the brain and peripheral tissues. Acts as a social neuromodulator with documented peripheral metabolic effects (reduced caloric intake, fat oxidation), analgesia, and uterotonic action. neuroendocrine
FDA approved Palmitoyl Tripeptide-1 Lipopeptide derived from a collagen I fragment studied for its matrikine signaling activity, stimulating fibroblasts to produce collagen, elastin, and hyaluronic acid in the dermal matrix. cosmetic-topical
Not FDA approved PT-141 Agonist of melanocortin receptors (MC3R and MC4R) in the central nervous system. Unlike vascular drugs (sildenafil), PT-141 acts directly on the brain to modulate sexual desire. hormonal-sexual-health
FDA approved Retatrutide Triple GIP/GLP-1/glucagon agonist, the first of its class in advanced clinical trials. Phase 2 reported average weight loss of 24% — greater than any approved peptide to date. metabolic-weight-loss
Investigational Selank Synthetic analog of tuftsin (TP-7) with anxiolytic, antidepressant, and nootropic properties. Unlike benzodiazepines, it does not produce sedation, dependence, or withdrawal symptoms. brain-health-nootropics
Not FDA approved Semaglutide Long-acting GLP-1 receptor agonist, approved for type 2 diabetes and obesity. Reduces blood glucose, suppresses appetite, and produces sustained weight loss. metabolic-weight-loss
FDA approved Semax Synthetic analog of ACTH fragment 4-7 with a Pro-Gly-Pro extension. Increases BDNF, CREB, and NGF in the brain. Approved in Russia for stroke, traumatic brain injury, and cognitive impairment. Considered one of the most studied nootropics. brain-health-nootropics
Not FDA approved Sermorelin Synthetic analog of the first 29 amino acids of GHRH. The first GH secretagogue used clinically for GH deficiency diagnosis. Produces physiological pulsatile release. growth-hormone-performance
Not FDA approved SNAP-8 Extended synthetic octapeptide analogue of the N-terminal SNAP-25 fragment, studied as an enhanced version of Argireline for inhibiting SNARE complex formation and reducing the appearance of expression lines. cosmetic-topical
Not FDA approved SS-31 Mitochondrial tetrapeptide that selectively binds to cardiolipin in the inner mitochondrial membrane. Restores mitochondrial function in tissues with ischemic damage, aging, or mitochondrial disease. One of the most clinically advanced mitochondrial peptides in development. longevity-mitochondrial-health
Investigational Survodutide Dual GLP-1/glucagon agonist developed by Boehringer Ingelheim. The only next-generation metabolic agent with specific clinical evidence in fatty liver disease (NAFLD/NASH). Phase 2 reported weight loss of 12.5–14.9% at 46 weeks. metabolic-weight-loss
Investigational Syn-ake Synthetic tripeptide that mimics the muscular-relaxation effect of Waglerin-1, a peptide found in Temple Viper venom, by competitively blocking nicotinic acetylcholine receptors at neuromuscular junctions. cosmetic-topical
Not FDA approved TB-500 Synthetic peptide analog of Thymosin Beta-4, studied in models of muscle, tendon, and cardiovascular repair. Acts on actin dynamics to promote cell migration. healing-recovery
Not FDA approved Tesamorelin Stable GHRH analog FDA approved for visceral fat reduction in HIV patients. Reduces abdominal visceral fat by 15–20% in clinical trials. Also studied for cognitive function in older adults. growth-hormone-performance
FDA approved Thymosin Alpha-1 28-amino-acid peptide derived from the thymic gland. Modulates the immune response by activating T cells, NK cells, and dendritic cells. Used in oncology, viral hepatitis, and autoimmune diseases in multiple countries. immune-inflammation
Not FDA approved Tirzepatide Dual GIP/GLP-1 agonist, the first of its class to be approved. Produces greater weight loss than semaglutide in head-to-head clinical trials. Unique mechanism that combines two metabolic pathways. metabolic-weight-loss
FDA approved